Daridorexant Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 25 mg, 50 mg
Reference Brands: Quviviq (USA/EU)
Category:
Neurology
Daridorexant is available in Tablets
and strengths such as 25 mg, 50 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Daridorexant is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Daridorexant can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Daridorexant, marketed under the brand name Quviviq, is an oral medication approved for the treatment of insomnia in adults, specifically for those experiencing difficulties with sleep onset and/or sleep maintenance. As a dual orexin receptor antagonist (DORA), daridorexant works by selectively blocking orexin receptors OX1 and OX2, helping to regulate the sleep-wake cycle and promote restful, continuous sleep.
Clinical studies have demonstrated that daridorexant significantly improves multiple measures of sleep. At doses of 25 to 50 mg, it reduces latency to persistent sleep (LPS) by 6 to 12 minutes, decreases wake after sleep onset (WASO) by 10 to 23 minutes, and increases subjective total sleep time (TST) by 10 to 22 minutes compared with placebo. Furthermore, at the 50 mg dose, daridorexant has been shown to enhance daytime functioning, supporting better alertness and cognitive performance during waking hours.
Taken orally once daily before bedtime, daridorexant provides a modern, targeted approach to insomnia management with a favorable tolerability profile. It offers patients a safe and effective option for improving both nighttime sleep quality and overall daytime well-being.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing